The curative approach to advanced gastric cancer treatment is surgical resection. But the risk of relapse after resection in this disease remains high. To address this, multiple perioperative local and systemic therapies have been tested in patients with operable gastric adenocarcinomas over the last two decades.
However, while the roles of neoadjuvant and adjuvant therapies have been evolving over the last two decades, many unanswered questions remain.
Here, we first discuss the scientific rationale for these interventions. Next, we review the current progress, and offer a perspective on potential approaches that may be useful in the perioperative setting in advanced gastric cancer.
Full Text Sources:
Abstract:
Views: 3415

Cited by 0 articles